NCT02234193

Brief Summary

The investigators are doing this research study to learn about how the skin heals after many microscopic skin biopsies are collected. Skin-grafting is a life-saving procedure for people with large area skin wounds caused by burns or trauma. Conventional autologous (self) skin grafting techniques require the creation of large donor site wounds, causing numerous complications including pain, infection, blistering, discoloration, and scarring. Based on previous research, many of these adverse effects can be improved, or even eliminated, by harvesting skin tissue in very small biopsies. These "micro-biopsies" are less than the size of a sewing pin. Then, they are put back together into a skin graft. This concept is based on clinical observations from fractional photothermolysis laser therapy, an FDA approved laser that has been previously developed by the investigators research group for the treatment of scars and ageing skin. With this laser technique, thousands to millions of small burns are produced by laser on a patient's skin, and the skin responds by healing the damaged areas to create new healthy skin within days and without scarring. Although the results of laser treatment are well-known, it is not known what happens when we harvest the skin using needles instead of using the laser to cut the skin. The investigators also would like to understand how the body heals the skin. Understanding how this works helps in understanding wound healing, and may lead to future treatments for healing large wounds, disfiguring burn scars, and preventing scar formation. A tummy tuck (abdominoplasty surgery) is done to remove excessive skin of the belly. This is an elective surgery, in other words, it is optional and usually done for cosmetics reasons (to improve the appearance). The skin of the belly that is removed during an abdominoplasty surgery (tummy tuck) is discarded. The skin of the area removed is called "pre-abdominoplasty skin". The investigators would like to study the effects of the micro-biopsies on pre-abdominoplasty skin to exam how the skin heals over time and to study the skin that will be removed during the abdominoplasty surgery. This is a pilot study. Pilot studies are done on a small group of subjects to learn if a larger study would be useful. The investigators are asking subjects to take part in this study who are healthy with an abdominoplasty surgery (tummy tuck) scheduled at Massachusetts General Hospital (MGH) by a plastic surgeon . The investigators will enroll about 28 subjects in this research study, all at MGH. The Department of Defense is paying for this study to be done.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for early_phase_1

Timeline
Completed

Started Jun 2016

Typical duration for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2014

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 9, 2014

Completed
1.7 years until next milestone

Study Start

First participant enrolled

June 1, 2016

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2019

Completed
Last Updated

March 2, 2026

Status Verified

February 1, 2026

Enrollment Period

2.7 years

First QC Date

August 27, 2014

Last Update Submit

February 26, 2026

Conditions

Keywords

wound healing

Outcome Measures

Primary Outcomes (1)

  • Evaluation of Efficacy - Change from baseline scarring at 8 weeks

    The extent of scarring caused by the harvesting of micro-skin columns will be assessed by investigators and patients using the Patient and Observer Scar Assessment Scale (POSAS) at all of the follow-up time points. Patient and Observer Scar Assessment Scale (POSAS)

    24 h, 1 week, 2 weeks, 4 weeks and 8 weeks post treatment

Secondary Outcomes (2)

  • Assessing Subject Side-effects - Change from baseline side-effects at 8 weeks

    day 0, 24 h, 1 week, 2 weeks, 4 weeks and 8 weeks after the procedure

  • Pain assessment - Visual Analog Scale (VAS) - Change from baseline pain at 8 weeks

    DAY 0, 24h, 1, 2, 4 & 8 weeks

Other Outcomes (2)

  • Histopathology examination

    8 weeks

  • Subject Satisfaction Survey - Change from baseline side-effects at 8 weeks

    Day 0, 24h, 1, 2, 4 & 8 Weeks

Study Arms (7)

Micro biopsies 2mm x control

ACTIVE COMPARATOR

2 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Micro biopsies 1mm x control

ACTIVE COMPARATOR

1 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Micro biopsies 0.8 mm x control

ACTIVE COMPARATOR

0.8 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Micro biopsies 0.6 mm x control

ACTIVE COMPARATOR

0.6 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Micro biopsies 0.5 mm x control

ACTIVE COMPARATOR

0.5 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Micro biopsies 0.40 mm x control

ACTIVE COMPARATOR

0.4 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Micro biopsies 0.20 mm x control

ACTIVE COMPARATOR

0.2 mm diameter micro biopsies will be performed on all subjects.

Device: Micro biopsyProcedure: Lidocaine with epinephrine

Interventions

This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site

Micro biopsies 0.20 mm x controlMicro biopsies 0.40 mm x controlMicro biopsies 0.5 mm x controlMicro biopsies 0.6 mm x controlMicro biopsies 0.8 mm x controlMicro biopsies 1mm x controlMicro biopsies 2mm x control

The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure

Also known as: Lidocaine
Micro biopsies 0.20 mm x controlMicro biopsies 0.40 mm x controlMicro biopsies 0.5 mm x controlMicro biopsies 0.6 mm x controlMicro biopsies 0.8 mm x controlMicro biopsies 1mm x controlMicro biopsies 2mm x control

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy adults (\>18 years old) scheduled to undergo elective abdominoplasty surgery at MGH, male or female.
  • Willingness to participate in the study
  • Willingness to undergo biopsies of full-thickness skin tissue from the pre-abdominoplasty skin, and have the biopsy sites marked by tattoos.
  • Informed consent agreement signed by the subject
  • Willingness to follow the treatment and follow-up schedules, and post treatment care requirements
  • Willingness to not use topical or systemic (oral) anti-scarring or anti-inflammatory\* medications during the study period.

You may not qualify if:

  • Subjects who are immunocompromised or immunosuppressed\*
  • Subject is unable to comply with treatment, home care or follow-up visits
  • Subject has an infection or other dermatologic condition in the area to be treated
  • Subjects with a personal or family history of keloid formation.
  • Subjects with pre-existing scars, tattoos, birthmarks, or other physical features in the area to be treated, such that the experimental outcome may be confounded.
  • Subjects with a history of coagulopathy, or are taking anticoagulants
  • Subjects taking daily oral aspirin.
  • Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
  • Subjects with any contraindications for elective abdominoplasty, as determined by their treating plastic surgeon and/or pre-op anesthesiologist.
  • Subjects with current drug or alcohol addiction.
  • Subjects who are pregnant and/or breastfeeding
  • Subjects with tape adhesive allergies
  • Subjects with known allergies to injectable lidocaine or other topical anesthetics
  • Subjects with uncontrolled or unstable chronic disease such as diabetes, hepatitis, hypertension, etc.
  • Subjects taking oral corticosteroids or topical steroids on the study area.
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wellman Center for Photomedicine, Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Related Publications (2)

  • Rasmussen CA, Tam J, Steiglitz BM, Bauer RL, Peters NR, Wang Y, Anderson RR, Allen-Hoffmann BL. Chimeric autologous/allogeneic constructs for skin regeneration. Mil Med. 2014 Aug;179(8 Suppl):71-8. doi: 10.7205/MILMED-D-13-00480.

  • Champlain AH, DiGiorgio CM, Zurakowski D, Sakamoto FH, Anderson RR. Wound Healing After Fractional Skin Harvesting. Dermatol Surg. 2022 Oct 1;48(10):1083-1088. doi: 10.1097/DSS.0000000000003552. Epub 2022 Aug 23.

MeSH Terms

Conditions

Cicatrix

Interventions

LidocaineEpinephrine

Condition Hierarchy (Ancestors)

FibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesEthanolaminesAmino AlcoholsAlcoholsBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Dermatology, Director of the Wellman Center for Photomedicine

Study Record Dates

First Submitted

August 27, 2014

First Posted

September 9, 2014

Study Start

June 1, 2016

Primary Completion

March 1, 2019

Study Completion

March 1, 2019

Last Updated

March 2, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

Locations